30 C
Vientiane
Wednesday, September 10, 2025
spot_img
Home Blog Page 458

Singapore-Based Innovative Biomedical Start-Up Achieves ‘Strategic Triumph’ to Conquer Chinese Med-Tech Market

  • NMPA grants Syntellix product approval for the world’s most important future market with more than 1.4 billion people
  • Syntellix’ product approval for China is the largest and most important success in the company’s history; product approval in China was the company’s most important strategic and operational goal
  • Syntellix had previously already been granted the accelerated ‘innovative pathway’ by the NMPA due to the exceptional benefits of its products
  • In total, product approvals for Syntellix products have accumulated to date in countries with more than 5.5 billion inhabitants; product approvals had already been achieved in 73 countries and regions on five continents before current success in China
  • Development of the prioritized core markets of China, India, and ASEAN is being carried out via Syntellix Asia Pte Ltd in Singapore as manufacturing facility & sales hub
  • Syntellix Asia Pte Ltd has been supported by the Singapore Economic Development Board (EDB); Syntellix AG targets IPO on the Singapore Exchange (SGX)
  • Syntellix and Syntellix Asia CEO Claassen: “After 7 years of focusing on China, we have achieved what almost everyone considered impossible. As a startup with its operational heart in Singapore, we have written a pioneering story worldwide, whose global medical success can now no longer be stopped. I sincerely thank the Singapore Economic Development Board (EDB) for its far-sighted contribution to the operational and structural foundation of our rollout in Asia by providing expertise and financial support for the establishment and expansion of our production facility in Singapore, which will now also become an Asia-wide and global sales hub as planned.”

HANOVER, Germany, and BEIJING and SINGAPORE, July 23, 2025 /PRNewswire/ — Syntellix AG, parent company of Singapore-based, Syntellix Asia Pte Ltd, has received product approval for the People’s Republic of China from the Chinese NMPA (National Medical Products Administration) in Beijing, which is responsible for the government regulation, registration, and monitoring of medical devices for the Chinese market. This product approval for the world’s most important future market, with more than 1.4 billion people, is by far the greatest and most important success in the company’s history. Syntellix AG had declared the development of the vast Chinese market its top strategic priority following Professor Dr Utz Claassen’s assumption of office as CEO of the company. After Syntellix had already previously been granted the accelerated ‘innovative pathway’ by the NMPA due to the particular advantages of its products, the initial approval process has now been completed extremely successfully. It was the most complex, intensive, and sophisticated approval process Syntellix has ever undergone in terms of product safety and quality management systems.

Syntellix now has obtained product approvals in countries with more than 5.5 billion inhabitants, or more than two thirds of the world’s population. Syntellix had previously received product approvals in 73 countries and regions on five continents, including all of Europe, Australia and New Zealand, South Africa, Singapore, Israel, and Saudi Arabia, as well as fast-growing, demographically dynamic countries such as Indonesia, Vietnam, the Philippines, and Thailand, as well as the world’s most populous country – India. China and India, with a combined population of almost 3 billion, open up entirely new dimensions of potential for the company in many respects. Syntellix’ highly innovative bioabsorbable metallic implants are produced by Syntellix Asia Pte Ltd which is based in JTC’s Tuas Biomedical Park. The Economic Development Board (EDB) had provided initial grants to Syntellix to support the establishment of its manufacturing presence and global sales hub in Singapore.

With the product approval now achieved in China, labelled by German news platform ‘Pressefeuer’ a ‘strategic triumph’ that could revolutionize the world of biomedical engineering and is a decisive step for the Hanover-based company’, Syntellix has achieved its most important strategic and operational goal. The strategic decision to develop the prioritized core markets of China, India, and ASEAN through Syntellix Asia Pte Ltd in Singapore, and to locate and expand the main production site in the ultra-modern and highly efficient island nation of Singapore, has proven to be both expedient and entirely correct. Establishing an Asia-centric production chain was strategically and operationally the right decision, as the production and sales hub in Singapore can supply and serve most of the world better and faster than from Germany or Europe. More than 3.5 billion people live in China, India, and the ASEAN region alone, which is more than 40 times the population of the Federal Republic of Germany, while at the same time experiencing significantly greater dynamics in terms of population growth, market growth, and economic power and perspectives.

For this purpose – establishing and expanding production in Singapore, tapping into the South Asian, Southeast Asian, and East Asian markets, and obtaining the necessary product approvals, particularly in China, – Syntellix, CEO Professor, Dr Utz Claassen, who is also Executive Chairman & CEO of Syntellix Asia Pte Ltd in Singapore, relocated his residence from Germany to Singapore more than five years ago in consultation and coordination with the Supervisory Board of Syntellix AG.

Syntellix CEO Professor Utz Claassen thus commented very positively on the product approval now achieved in China: “After more than 17 years of work and more than 7 years of focusing on China alone, we have achieved what almost everyone considered impossible. As a startup from Hanover with ist operational heart in Singapore, we have written a pioneering story worldwide, whose global medical success is now unstoppable. Those who win in China are strategically and operationally ideally positioned. The largest hospitals in China individually have higher patient volumes and more operations for our highly innovative products than most countries in the European Union. Without neglecting our homeland, we are proud and grateful to now be able to use our products, which are so beneficial for patients, users, and the healthcare system, in China, with its 5,000 years of cultural history, its magnificent medical tradition, and its unique future prospects. This is a game changer for our company, both qualitatively and quantitatively.”

Claassen emphasizes both the abstract and concrete positive conditions for the successful development of Syntellix’ activities in Asia, and also specifically in Singapore, and he is grateful for the very positive environment here: “I would like to expressly thank our outstanding Chinese partners for their tremendous support and cooperation, and the NMPA for an outstandingly differentiated and structured approval process. I would also like to sincerely thank the Singapore Economic Development Board (EDB) for its far-sighted contribution to the operational and structural foundation of our rollout in Asia by providing expertise and financial support for the establishment and expansion of our production facility in Singapore, which will now also become an Asia-wide and global sales hub as planned. This will create many attractive jobs in Singapore and set new international standards in biomedical engineering under market conditions that are not found in Germany or Europe, and building on government funding from the Republic of Singapore.”

Syntellix AG, as a joint-stock company under German stockholding law already a public company, also targets an IPO on the Singapore Exchange (SGX), the preparations of which have already been ongoing for several years with the help of Singaporean banks and law firms, well supported by SGX management under the leadership of its CEO Mr Loh Boon Chye and coordinated by Ms Alice Gwee.

About Syntellix:

Syntellix AG, a global pioneer in biomedical engineering, materials, and life sciences, is the only company in the world with approvals for bioabsorbable metallic implants in more than 70 countries on five continents, tens of thousands of successful surgeries, and the highest level of patient satisfaction. Syntellix is a global protagonist and market and technology leader in the field of bioabsorbable metallic orthopaedic implants. The company has received numerous prestigious awards and prizes, including the Innovation Award of the German Economy, the German Healthcare Industry Future Award, the German Medical Award, the STEP Award, the “Innovator of the Year” award, the German Innovation Award in Gold, and the Sustainability Award as “Product of the Year.” More than 50 medical and scientific publications have meanwhile documented the safety, efficacy, and reliability of the MAGNEZIX® implants developed by Syntellix, which have been described as “advantageous” and even “clinically superior” to conventional titanium implants for numerous clinical applications.

Syntellix Asia Pte Ltd in Singapore is a wholly-owned subsidiary of Syntellix AG. It is the operational heart of the group. The manufacturing facility for the highly innovative MAGNEZIX® implants is located in Singapore, in JTC’s Biomedical Park in Tuas. Syntellix Asia Pte Ltd, which in turn has the subsidiaries Syntellix China Pte Ltd, Syntellix Philippines Incorporated in San Juan City, and Syntellix India Private Limited in New Delhi and Jaipur, Rajasthan, serves not only the internationally leading medical hub of Singapore itself with its numerous world-class hospitals, but also major markets in countries throughout the ASEAN region, including Thailand, Malaysia, Vietnam, and Indonesia.”

Contact:
T +49 511 270 413 50
F +49 511 270 413 79
info@syntellix.com
www.syntellix.com 

 

Oudomxay to Establish 40 Ta Saeng Sub-Districts, After Vientiane’s Pilot Project

Laos' Oudomxay Province. (Photo credit: Hope Vision Photography)

Northern Laos’ Oudomxay Province will establish 40 new Ta Saeng (sub-district) administrative units as part of Laos’ ongoing effort to strengthen local governance and improve public service delivery.

This initiative will cover the province’s seven districts and a total of 466 villages.

Each Ta Saeng in Oudomxay will oversee between one and 24 villages, with governing committees comprising a chairperson, one or two vice-chairpersons, and additional officials selected from civil servants and qualified local candidates. 

The committees will focus on governance, economic planning, cultural development, and national security while coordinating with the Lao People’s Revolutionary Party and mass organizations.

A pilot Ta Saeng was successfully launched in May in Xaythany District, Vientiane Capital, covering 23 of the district’s 104 villages.

Ta Saeng in Laos, first introduced during the French colonial period in the 1920s to facilitate governance. The system was abolished in the 1990s.

Recent Constitutional Amendments, Government Restructuring

This move, introduced by the Ministry of Home Affairs on 21 January, is expected to establish approximately 950 sub-districts nationwide. The plan involves dividing districts into smaller administrative units, with an average of 6 to 7 sub-districts per district. Each sub-district will oversee between 1 and 24 villages, depending on local needs, geography, and population size.

This administrative overhaul aligns with the constitutional amendments and broader government restructuring approved during the 2nd Extraordinary Session of the 9th legislature of the National Assembly on 20 March. 

All 156 members of the National Assembly endorsed a plan to reduce the number of ministries from 17 to 13, merging several key bodies to eliminate overlaps and improve operational efficiency.

On 26 June, the Lao National Assembly ended its 9th Ordinary Session, cutting ministries from 17 to 13, reshuffling leadership, and approving new laws to streamline government, boost governance, and enhance public services nationwide.

NetDragon Achieves “A” Rating in Wind ESG Assessment, Demonstrating Strong Commitment to Sustainable Development Principles

HONG KONG, July 23, 2025 /PRNewswire/ — NetDragon Websoft Holdings Limited (“NetDragon” or the “Company”, Hong Kong Stock Code: 777), a global leader in building internet communities, is pleased to announce that it has achieved an “A” rating in the latest 2025 ESG assessment conducted by Wind Information Co.,Ltd (“Wind”), in recognition of its outstanding performance in environmental protection, social responsibility, and corporate governance. Wind defines an “A” rated company as one with high management standards, low ESG risks, and strong capabilities for sustainable development. Among the 105 listed software companies assessed this year, NetDragon ranked 6th. The Company also achieved scores above the industry average across all three dimensions: Environment, Social, and Governance, underscoring its comprehensive strength and leading position in sustainability.

Wind is a leading provider of financial data and analytics services in China. The Wind ESG Rating framework is composed of assessment towards managerial practices and controversy events, aligning with the foundation of international standards while adapting to the characteristics of China’s capital market. Leveraging its strong data capabilities, Wind has constructed a data‑driven ESG rating system that currently covers more than 12,000 corporate entities in the Greater China region, including all A‑share and Hong Kong‑listed companies, as well as public bond issuers.

NetDragon has consistently integrated sustainability into its business operations and product development. The Company is committed to fulfilling its social responsibilities, enhancing governance structures, and driving industry-wide and societal progress through technological innovation and global expansion. Through a wide range of initiatives, NetDragon continues to advance sustainability: in environmental protection, it actively explores best practices in energy conservation, carbon reduction, and green operations. NetDragon’s digital education products are deployed in over 2 million classrooms across 192 countries, fostering the global adoption of green education concepts. On the social front, the Company promotes philanthropic programs, advances education equity, and enhances public welfare through its distinctive “Gaming + Philanthropy” model, integrating digital innovation with meaningful social impact. In June, NetDragon partnered with the Xishuangbanna Tropical Rainforest Conservation Foundation to launch the “Towards the Future: Asian Elephant Rescue Action (象往未来•亚洲象救助行动),” leveraging gamified features in Eudemons Online to raise public awareness of wildlife protection. In corporate governance, NetDragon adheres to transparent, robust, and compliant governance practices, continuously creating long‑term value in line with ESG principles.

Through its ongoing commitment to ESG excellence, NetDragon has garnered broad recognition from both the industry and the wider community. The Company received “BBB” in MSCI ESG rating, surpassing the industry average in the “Privacy and Data Security” category. Furthermore, NetDragon was rated as a “low risk” company by the reputable rating agency Morningstar Sustainalytics, placing it among the top performers in the software and services industry. Recently, NetDragon’s digital education solutions won the “Education Innovation & Technology – Rising Star Award” at the “2025 Hong Kong Sustainable Development Innovation and Technology Awards,” organized by the World Institute of Sustainable Development Planners (WISDP) and sponsored by the Innovation and Technology Commission of the Government of the HKSAR. NetDragon’s innovative case was also included in the 2025 Hong Kong Sustainable Development Innovation & Technology Solutions Report.

Looking ahead, NetDragon will continue to advance its ESG initiatives by enhancing management practices and disclosure standards, and furthering the development of its “Gaming+” model and digital education innovations. The Company aims to collaborate closely with global partners to promote cultural heritage, environmental sustainability, and educational equity, thereby creating long‑term, sustainable value for both society and the environment.

About NetDragon Websoft Holdings Limited   

NetDragon Websoft Holdings Limited (HKSE: 0777) is a global leader in building internet communities with a long track record of developing and scaling multiple internet and mobile platforms that impact hundreds of millions of users, including previous establishments of China’s first online gaming portal, 17173.com, and China’s most influential smartphone app store platform, 91 Wireless.    

Established in 1999, NetDragon is one of the most reputable and well-known online game developers in China with a history of successful game titles including Eudemons Online, Heroes Evolved, Conquer Online, and Under Oath. In the past 10 years, NetDragon has also achieved success with its online education business both domestically and globally, and its overseas education business entity, currently a U.S.-listed subsidiary named Mynd.ai, is a global leader in interactive technology and its award-winning interactive displays and software can be found in more than 1 million learning and training spaces across 126 countries.   

For investor enquiries, please contact:  
NetDragon Websoft Holdings Limited  
Ms. Maggie Zhou
Senior Director of Investor Relations  
Email: maggiezhou@nd.com.hk  / ir@netdragon.com   
Website: ir.netdragon.com     

2025 Zhejiang-Japan Travel Exchange Seminar Highlights Bilateral Tourism Cooperation

TOKYO, July 23, 2025 /PRNewswire/ — The 2025 Zhejiang-Japan Tourism Exchange Seminar, hosted by the Zhejiang Provincial Department of Culture, Radio, Television and Tourism, was successfully held in Tokyo on July 10. The event furthered bilateral tourism cooperation, promoted Zhejiang’s broad array of inbound travel offerings, and identified pathways to deepen Zhejiang’s engagement with the Japanese market while strengthening cultural and tourism ties.

To highlight Zhejiang’s distinct tourism assets, industry representatives from both regions delivered keynote remarks, outlining market trends and opportunities for future collaboration. New itineraries developed to meet the expectations of the Japanese outbound travel market were introduced, drawing considerable interest and active participation from attendees.

Tourism fosters connection, cultural exchange, and shared understanding. The growing tourism relationship between China and Japan has become a meaningful conduit for building mutual respect and long-term friendship. The seminar not only emphasized Zhejiang’s wide-ranging tourism attractions but also served as a valuable forum for supporting international tourism partnerships. With continued collaboration between industry stakeholders, Zhejiang and Japan are well-positioned to expand their tourism cooperation, pursue sustainable growth, and promote mutual economic and cultural benefit. 

 

Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure

ZUG, Switzerland, July 23, 2025 /PRNewswire/ — Berlin Heals and the C-MIC II Investigators today announced the publication of the C-MIC II trial results in the European Journal of Heart Failure. The study, titled “Cardio-microcurrent Device Treatment for Heart Failure with Reduced Ejection Fraction: Results from the C-MIC II Open Label Randomized Controlled Trial,” was previously presented as a Late-Breaking Clinical Trial (LBCT) at the 2025 ESC-HFA Congress in Belgrade.

 

The findings mark a major advancement in the field of bioelectronic medicine for heart failure, highlighting the potential of the Cardio-Microcurrent (C-MIC) device—a novel implantable system that delivers low-intensity microcurrent to the failing myocardium.

Study Summary

In this open-label, randomized controlled trial, 70 ambulatory patients with non-ischemic dilated cardiomyopathy, LVEF 25–35%, and NYHA Class III–IV symptoms were randomized 1:1 to receive C-MIC therapy plus guideline-directed medical therapy (GDMT) or GDMT alone. The primary endpoint was the difference in change in LVEF at 6 months. Secondary endpoints included change in NYHA class, 6-minute walk distance (6MWD), and Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS).

At six months, patients receiving C-MIC therapy experienced markedly greater improvements than controls across all prespecified endpoints. Left-ventricular ejection fraction (LVEF) rose by an average of 6.6% in the C-MIC group versus 1.5% in the control group, yielding a mean between-group difference of 5.1% (95 % CI 3.1–7.1; p < 0.001). Clinically meaningful functional gains were similarly superior: 84 % of C-MIC patients improved by at least one NYHA class compared with 15 % of controls—a risk difference of 68.9 % (95 % CI 50.6–87.2; p < 0.001). Quality-of-life also benefited, with 75 % of C-MIC patients achieving a ≥5-point increase in KCCQ Overall Summary Score versus 15 % in controls (risk difference 60.0 %, 95 % CI 42.3–77.6; p < 0.001). Finally, nearly half of treated patients (47 %) attained at least a 30 % rise in six-minute-walk distance compared with only 9 % of controls (risk difference 38.3 %, 95 % CI 14.4–62.2; p = 0.002), underscoring consistent benefit across structural, symptomatic, and functional outcomes. The therapy was well tolerated, with no device-related serious adverse events reported.

Author and Investigator Quotes

“This study offers compelling evidence that microcurrent therapy can enhance both cardiac function and patient-centered outcomes in individuals with HFrEF,” said Prof. Jesus E. Rame, co-first author, The Louis R. Dinon MD Professor of Medicine and Surgery and Enterprise Chief of Advanced Cardiac and Pulmonary Vascular Disease at Thomas Jefferson University. “These findings introduce a promising new therapeutic avenue for patients who remain symptomatic despite receiving optimal medical therapy.” Dr. Rame further noted, “This randomized controlled trial not only demonstrates the efficacy and safety of the therapy in patients with stable, chronic ambulatory heart failure, but also pioneers an entirely novel treatment paradigm aimed at restoring cardiac function in non-ischemic cardiomyopathy.”

“This was a remarkable collaborative effort across all participating sites,” said Prof. Dragana N. Kosevic, co-first author and co-Principal Investigator at Dedinje Cardiovascular Institute, Belgrade. “We observed meaningful improvements in symptoms and functional capacity among our patients—an encouraging sign for broader clinical adoption.”

Prof. Jan Schmitto, Professor of Cardiac Surgery at the Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, co-first author and coordinating investigator of the trial, commented: “These results validate more than a decade of translational work. They suggest that restoring myocardial bioelectric signaling can have a direct and clinically meaningful impact on cardiac performance in patients with advanced heart failure.”

Prof. Stefan D. Anker, senior author and Professor of Cardiology at Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin added: “This is the first randomized trial to demonstrate that low-level microcurrent stimulation can improve both structural heart function and quality of life. It establishes a strong foundation for future studies focused on long-term clinical outcomes.”

“We are thrilled to see the C-MIC II results published in the European Journal of Heart Failure,” said John Brumfield, CEO of Berlin Heals “These findings support our mission to develop breakthrough, bioelectronic therapies for chronic heart failure—targeting the disease at its electrical and cellular roots.”

To access the full publication in European Journal of Heart Failure, please visit https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.3763

Disclaimer:

The C-MIC device is investigational and not approved for commercial use in any jurisdiction. Its safety and effectiveness are still under evaluation.

Zylox-Tonbridge Issues Positive Profit Alert, Expects Over RMB 115 Million in 1H 2025 Net Profit

HANGZHOU, China, July 23, 2025 /PRNewswire/ — Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, “Zylox-Tonbridge” or the “Company”), a leading medical device company in China’s peripheral and neurovascular interventional market, today announced a positive profit alert for the six months ended June 30, 2025. Based on preliminary unaudited figures, the Company expects to record revenue of over RMB 480 million, representing a year-on-year increase of approximately 31.1%. Net profit is anticipated to exceed RMB 115 million, reflecting a robust growth of approximately 66.9% compared to the same period in 2024.

The strong performance was primarily driven by the continued expansion of the Company’s neurovascular and peripheral vascular intervention businesses, as well as further improvements in operational efficiency. Key products such as the Kylin™ Flow Diverter, neurovascular guidewires, UltraFree® Drug-Coated PTA Balloon Catheter, and Zylox Octoplus™ Vena Cava Filter delivered significant sales growth and steadily expanded market share during the reporting period.

In addition to commercial expansion, Zylox-Tonbridge also accelerated the launch of innovative products. In the first half of 2025, the ZYLOX Eagle™ Peripheral Thrombus aspiration system received marketing approval from China’s National Medical Products Administration (NMPA), further enriching the Company’s product portfolio and enhancing its comprehensive treatment solutions.

The Company also made notable progress in international markets. Several core products obtained regulatory approvals and achieved initial commercial sales in key emerging markets in Southeast Asia, the Middle East, and South America—marking a new phase of accelerated global expansion.

Looking ahead, Zylox-Tonbridge remains committed to its mission of “Innovation for Quality Life”. The Company will continue to invest in medical technology innovation and strive to provide high-quality, and affordable solutions for patients worldwide. By advancing the adoption of innovative technologies, Zylox-Tonbridge aims to contribute to the sustainable development of the global healthcare ecosystem.

Samsung Biologics reports second quarter 2025 financial results

  • Recorded Q2’25 consolidated revenue of KRW 1,289.9 billion
  • Recorded Q2’25 consolidated operating profit of KRW 475.6 billion
  • Solid momentum sustained through capacity ramp-up and stable project execution

INCHEON, South Korea, July 23, 2025 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025.

“Our second quarter results demonstrate continued strong momentum across our business,” said John Rim, CEO and President of Samsung Biologics. “With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value—setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence.”

SECOND QUARTER 2025 RESULTS

Samsung Biologics posted consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion in the second quarter of 2025. On a standalone basis, the company reported revenue of KRW 1,014.2 billion and operating profit of KRW 477.0 billion. The growth was buoyed by the full utilization of Plants 1 through 3 and the continued ramp-up of Plant 4.

In the first half of 2025, standalone revenue surpassed KRW 2 trillion, reflecting consistent momentum across all manufacturing plants. Sales contract volume in the first half reached USD 2.4 billion, bringing up the cumulative value to USD 18.7 billion.

[Consolidated Earnings, KRW billion]   

Q2’25

Q2’24

YoY Change

Revenue

1,289.9

1,156.9

133.0

Operating Profit

475.6

434.5

41.1

EBITDA

653.8

582.6

71.2

BUSINESS UPDATES

In April, Samsung Biologics added 180 kL of capacity with Plant 5 to better meet clients’ manufacturing needs. The facility, equipped with advanced automation and digital systems, integrates best practices and features from existing plants to ensure consistent operations and the highest quality standards.

The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilizes patient-derived organoids to support drug discovery and development. Samsung Organoids enables precision screening to predict patient-specific drug responses and provides clients with multi-modal insights to effectively support early-stage decision making.

In May, Samsung Biologics announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis. Through the financial and legal separation, the company will focus on strengthening its core capabilities as a pure-play CDMO, enhancing customer satisfaction and proactively responding to the industry’s greater demands to ultimately maximize corporate value and sustainable growth potential.

On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management. As part of its decarbonization efforts, Samsung Biologics achieved a 24% reduction in greenhouse gas emissions in 2024 compared to the previous year and increased its renewable energy use to 29% of total electricity consumption. The company also signed an additional solar Power Purchase Agreement to further support its energy transition. Beyond operations, Samsung Biologics is actively engaged in collaborative efforts through the Sustainable Market Initiative to decarbonize healthcare supply chains and promote global environmental responsibility.

About Samsung Biologics

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region.

Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health.

For more information, please visit https://samsungbiologics.com/.

Samsung Biologics Media Contact

Claire Kim, Head of Marketing & Global Communications
cair.kim@samsung.com 

Asian markets accept that free trade with the US is a thing of the past, says UOBAM

SINGAPORE, July 23, 2025 /PRNewswire/ — Asian markets have continued to demonstrate resilience, even in the face of US tariffs. In a Special Report published today, UOB Asset Management (UOBAM) assesses that Asian markets could even rally if negotiations ahead of the new 1 August deadline result in improved rates relative to those announced in April. The implication here is that investors no longer expect a return to previous trading arrangements but are nevertheless sanguine about the region’s ability to withstand moderate tariffs.

Colin Ng, UOBAM’s Head of Asian Equities, explains, “The majority of Asian economies are likely to recover relatively quickly from the direct impact of US tariffs. A slowdown in exports to the US can be offset by trading with other countries, and in particular, with their Asian neighbours”

“This is because, on the one hand, more and more Asian companies are building globally recognisable brands, and on the other, the Asian consumer base is now large and affluent enough to absorb these products. That is why ASEAN has taken over from the US as China’s biggest trading partner.”

The UOBAM Special Report, entitled “Will US tariffs detail Asia’s growth?” looks at the short- and longer-term implications of US tariffs on seven markets in Asia, including the big exporters such as Korea, Taiwan region and Singapore as well as those more domestically-focused such as Malaysia and Indonesia.

Ng warns that the risk to Asian economies comes instead from the indirect impact of US tariffs, that is. if the tariffs result in a global growth slowdown or a recession. This is turn would cause the global demand for Asian exports to shrink. However, based on the economic data released so far, Ng says this is not UOBAM’s base case.  

Read the full report: https://www.uobam.com.sg/insights/will-us-tariffs-derail-asia-growth.page

About UOB Asset Management

UOB Asset Management Ltd (UOBAM) is a wholly-owned subsidiary of United Overseas Bank Limited. Established in 1986, UOBAM has nearly 40 years of experience in managing collective investment schemes and discretionary funds in Singapore, making us among the largest unit trust managers by assets under management. As of 30 June 2025, we manage 65 unit trusts in Singapore and together with our subsidiaries, oversees S$37.6 billion in clients’ assets.

Headquartered in Singapore, UOBAM has a strong presence across Asia, with business and investment offices in Brunei, Indonesia, Japan, Malaysia, Thailand and Vietnam. Our network includes UOB Islamic Asset Management Sdn Bhd in Malaysia, a joint venture with Ping An Fund Management Company Limited and strategic alliances with partners such as Wellington Management Singapore.

UOBAM is one of the region’s most awarded asset managers, with over 380 awards won. In 2025, we were recognised as the Best Regional Asset Management Company by the Asia Asset Management and previously named Best Asset Management House in Asia – 20 Years in 2023. Our digital innovation has also earned top honours, including Best Digital Wealth Management in Asia[1] and Best Robo Advisory Initiative[2] for 3 consecutive years as of 2024.

As a leader in sustainable investing, UOBAM was awarded Best application of ESG in ASEAN[3] (2023) and has received multiple sustainability accolades in Indonesia and Thailand. Our artificial intelligence capabilities were also recognised with the Most Innovative Application of Artificial Intelligence (ASEAN) for 2 consecutive years[4].

Connect with us: LinkedIn | Facebook

[1] Awarded by Asia Asset Management

[2] Awarded by The Digital Banker for the Global Retail Banking Innovations Award

[3] Awarded by Asia Asset Management

[4] As of 2025, by Asia Asset Management